Area of research
Oncology · Surgery
Research interest
Research focused on Metastasis and Dabrafenib, with related work in Motility, Cancer research, Ex vivo. Notable publications include 'Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial', 'Targeting tumor cell motility as a strategy against invasion and metastasis', and 'Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)'.
Prostate cancer cells synergistically defend against <scp>CD8</scp><sup>+</sup> T cells by secreting exosomal <scp>PD‐L1</scp>
Tripterygium glycosides reverse chemotherapy resistance in ovarian cancer by targeting the NRF2/GPX4 signal axis to induce ferroptosis of drug-resistant human epithelial ovarian cancer cells
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
Liver metastases: Microenvironments and <i>ex-vivo</i> models
Targeting tumor cell motility as a strategy against invasion and metastasis
Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Targeting tumor cell motility as a strategy against invasion and metastasis
DSpace@MIT (Massachusetts Institute of Technology) 2013cited by 5position: middle